Screener / SEC EDGAR /CIK 0001717115 /10-K filed Feb 24, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Technology · Internet & Software Services

Tempus AI, Inc. TEM

Compare with peers Embed
Earnings releases

Latest results release: Nov 2, 2026

8-K item 2.02, exhibit 99

What TEM's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

Adjusted EBITDA is defined as net income (loss), adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) provision for (benefit from) income taxes, (v) losses on equity method investments, (vi) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, (vii) the stock-based compensation adjustments, and (Viii) the G-4 Special Payment. release Aug 6, 2024

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 2, 2026 · EX-99.1

Tempus Reports Third Quarter 2026 Results

Open on SEC

Exhibit 99.1 Tempus Reports Third Quarter 2026 Results CHICAGO, November 2, 2026— Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026.

“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications,” said Eric Lefkofsky, founder and CEO of Tempus. “These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter.”

For the three-month period ended September 30, 2026, as compared to the same period in 2025:

• Increasing full year 2026 revenue guidance to $1.60 to $1.605 billion and expect full year Adjusted EBITDA of ~$65 million

• Announced multi-year strategic collaboration with Merck and Moderna to support commercialization of their individualized neoantigen therapy (INT) class of drugs

For the three-month period ended September 30, 2026, as compared to the same period in 2025:

• Diagnostics generated $303.5 million of revenue, representing 20% growth, driven by Oncology volume growth of 32%, offset by Hereditary revenue growth of 3%.

• Data and Applications generated $108.1 million of revenue, representing 33% growth, with Insights growing 29%.

• Gross profit increased 27% to $266.7 million, led by growth in Data and Applications.

• Net loss was $(14.9) million, which included $50.8 million of stock-based compensation expense and related employer payroll taxes and $42.8 million in unrealized gains on marketable securities, compared to a net loss of $(80.0) million in Q3 of 2025.

• Announced a strategic collaboration with BMS in October through which Tempus is directly licensing to BMS oncology data and models for up to $137.5 million over a five-year term. In addition, BMS and Pathos are licensing data for patients with Alzheimer's or dementia for $55 million over a five-year term, extending Tempus’ data and modeling platform beyond oncology.

• Announced a multi-year strategic collaboration with Merck and Moderna to support the potential commercialization of intismeran autogene, a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completed resected stage IIB-IV melanoma and other cancer types. • Cleared regulatory review of pending acquisition of Personalis (Nasdaq: PSNL). Personalis' shareholder meeting to approve the acquisition is planned for November 30, 2026. • Received two 510(k) clearances from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH and ECG-MR, expanding our non-invasive AI cardiology footprint. • Announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. Third Quarter Financial Results

Financial Outlook and Guidance Tempus is increasing its full year 2026 revenue guidance to $1.60 to $1.605 billion, which represents ~25% annual growth. We continue to expect 2026 Adjusted EBITDA to be ~$65 million. For additional information on the quarter, including a letter from our CEO and CFO, please visit our investor relations site at investors.tempus.com. Webcast and Conference Call Information A conference call and webcast will begin today, November 2, 2026 at 8:45 a.m. Eastern Time. Interested parties may access details at: Conference ID: 579 261 752 United States (Toll-Free): (833) 461-5787 International (Toll): +1 (585) 542-9983 Live webcast can be accessed here The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter by Eric Lefkofsky, Founder and CEO, and Jim Rogers, CFO, which will be discussed on the conference call and webcast. About Tempus Tempus is a technology company making precision medicine a reality through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of de-identified multimodal data and an intelligent operating system that makes that data accessible and actionable, Tempus connects AI, diagnostics and clinical workflows to deliver more personalized patient care and accelerate the discovery, development and delivery of better medicines. By continuously transforming data into insights, Tempus is building a learning healthcare ecosystem in which every patient can benefit from the treatment and experiences of those who came before.

For more information, visittempus.comand follow Tempus onLinkedIn,Instagram, andX.

In addition to the financial information presented in this release in accordance with accounting principles generally accepted in the United States of America (GAAP), Tempus also presents adjusted non-GAAP financial measures.

Non-GAAP gross profitis defined as GAAP gross profit, excluding stock-based compensation expense and employer payroll tax related to stock-based compensation (collectively, the “stock-based compensation adjustments”).Non-GAAP gross marginis defined as gross profit, excluding the stock-based compensation adjustments, as a percentage of revenue.Non-GAAP operating expensesare calculated as the sum of technology research and development expense, research and development expense, and selling, general and administrative expense, excluding the stock-based compensation adjustments, acquisition-related expenses, amortization of intangibles due to acquisition, and franchise taxes related to IPO.Non-GAAP income (loss) from operationsis defined as loss from operations, adjusted to exclude (i) the stock-based compensation adjustments, (ii) acquisition-related expenses, (iii) franchise taxes related to IPO, and (iv) amortization of intangibles due to acquisition.Non-GAAP net income (loss)is defined as net loss, adjusted to exclude (i) changes in fair value of our marketable equity securities and indemnity-related holdback liabilities, (ii) the stock-based compensation adjustments, (iii) acquisition-related expenses, (iv) amortization of intangibles due to acquisition, (v) losses (gains) from equity method investments, (vi) provision for (benefit from) income taxes, (vii) franchise taxes related to IPO, (viii) amortization of deferred other income from our IP License Agreement with SB Tempus, and (ix) loss on debt extinguishment.Non-GAAP net income (loss) per shareis defined as non-GAAP net income (loss) divided by weighted average common shares outstanding, basic and diluted.

Adjusted EBITDAis defined as net loss, adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) provision for (benefit from) income taxes, (v) losses (gains) from equity method investments, (vi) changes in fair value of our marketable equity securities and indemnity- related holdback liabilities, (vii) the stock-based compensation adjustments, (viii)acquisition-related expenses, (ix) amortization of deferred other income from our IP License Agreement with SB Tempus, (x) franchise taxes related to our IPO, and (xi) loss on debt extinguishment.

Tempus believes these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by institutional investors and the analyst community to help them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non- GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.

Tempus does not provide guidance for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and similarly cannot provide a reconciliation between Tempus’ forecasted Adjusted EBITDA and net loss without unreasonable effort due to the unavailability of reliable estimates for certain components of net loss and the respective reconciliations. These forecasted items are not within Tempus’ control, may vary greatly between periods, and could significantly impact future financial results.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”),and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, Tempus’ expected financial results for full year 2026; expectations concerning Tempus' collaborations and partnerships; Tempus' competitive position; and the pending acquisition of Personalis. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward- looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may

affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments, including Tempus' ability to consummate the acquisition of Personalis on the contemplated terms or at all and Tempus’ ability to realize the expected benefits of the acquisition of Paige AI, Ambry Genetics, Deep 6 AI, Center Health, and, if consummated, Personalis; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on February 24, 2026, as well as in other filings Tempus may make with the SEC from time to time. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Source: Tempus AI, Inc. Tempus AI, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (in thousands, except per share amounts)

(1) Includes related party revenue from Pathos AI, Inc. of $0 and $225 for the three months ended September 30, 2026 and 2025, respectively. Includes related party revenue from Pathos AI, Inc. of $190 and $226 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 16, Related Parties. (2) Includes related party revenue from Pathos AI, Inc. of $22,061 and $24,907 for the three months ended September 30, 2026 and 2025, respectively. Includes related party revenue from Pathos AI, Inc. of $65,718 and $41,445 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 16, Related Parties. Also includes related party revenue from SB Tempus Corp. of $0 and $6,253 for the three months ended September 30, 2026 and 2025, respectively. Includes related party revenue from SB Tempus Corp. of $6,241 and $18,743 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 7, Joint Venture. (3) Includes related party other income from SB Tempus Corp. of $3,989 for each of the three months ended September 30, 2026 and 2025. Includes related party other income from SB Tempus Corp. of $11,966 for each of the nine months ended September 30, 2026 and 2025. Refer to Note 7, Joint Venture.

Tempus AI, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands, except share and per share amounts)

September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current Assets Cash and cash equivalents $ 590,479 $ 604,787 Accounts receivable(1), net of allowances of $4,378 and $2,755 at 380,744 311,170 September 30, 2026 and December 31, 2025, respectively Inventory 53,773 51,724 Related party asset 17,500 8,785 Prepaid expenses and other current 47,507 40,498 assets Marketable equity 46,874 150,211 securities Total current assets $ 1,136,877 $ 1,167,175 Property and equipment, net 95,186 89,156 Goodwill 488,142 470,211 Intangible assets, net 293,815 349,202 Capitalized software, net 40,561 6,051 Marketable equity securities, less 212,276 — current portion Investments and other 16,241 21,111 assets Investment in joint venture 77,635 86,557 Investment in related party 17,500 — Related party asset, less current 10,208 16,215 portion Operating lease 58,402 64,496 right-of-use assets Restricted cash 4,755 4,664 Total Assets $ 2,451,598 $ 2,274,838 Liabilities, Convertible redeemable preferred stock, and Stockholders' equity Current Liabilities Accounts payable 70,506 81,994 Related party payable 10,000 — Accrued expenses 232,976 155,370 Deferred revenue(2) 85,931 92,673 Deferred other income(3) 11,966 15,955 Other current liabilities 12,146 8,680 Operating lease liabilities 11,584 13,355 Accrued data licensing fees 1,296 4,361 Total current liabilities $ 436,405 $ 372,388

(1) Includes related party accounts receivable from Pathos AI, Inc. of $12,092 and $6,428 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 16, Related Parties. Also includes related party accounts receivable from SB Tempus Corp. of $318 and $173 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 7, Joint Venture. (2) Includes related party deferred revenue from Pathos AI, Inc. of $103 and $3,938 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 16, Related Parties. Also includes related party deferred revenue from SB Tempus Corp. of $0 and $6,235 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 7, Joint Venture. (3) Deferred other income balances solely related to SB Tempus Corp. Refer to Note 7, Joint Venture.

Tempus AI, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands, except share and per share amounts)

September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Operating lease liabilities, less 69,483 74,272 current portion Convertible 175,967 208,672 promissory note Other long-term 51,449 56,600 liabilities Revolving credit — 100,000 facility Interest payable 22,501 12,393 Long-term debt, net — 202,753 Convertible senior 1,174,877 728,078 notes, net Deferred other income, less current — 7,977 portion(3) Deferred revenue, 20,514 20,379 less current portion Total Liabilities $ 1,951,196 $ 1,783,512 Commitments and contingencies (Note 8) Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at September 30, 2026 $ — $ — and December 31, 2025, respectively, no shares outstanding at September 30, 2026 and December 31, 2025 Stockholders' equity Class A Common Stock, $0.0001 par value, 1,000,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; 18 17 177,182,062 and 173,235,428 shares outstanding at September 30, 2026 and December 31, 2025, respectively Class B Common Stock, $0.0001 par value, 5,500,000 shares authorized at September 30, 2026 and December 31, 2025, 1 1 respectively; 5,043,789 outstanding at September 30, 2026 and December 31, 2025, respectively Treasury Stock, 203,431 and 183,229 shares at September (6,642 ) (6,642 ) 30, 2026 and December 31, 2025, respectively, at cost Additional paid-in 3,037,849 2,892,910 capital Accumulated other 166 902 comprehensive income Accumulated deficit (2,530,990 ) (2,395,862 ) Total Stockholders' $ 500,402 $ 491,326 equity Total Liabilities, Convertible redeemable preferred $ 2,451,598 $ 2,274,838 stock, and Stockholders' equity

(3) Deferred other income balances solely related to SB Tempus Corp. Refer to Note 7, Joint Venture.

Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)

Nine Months Ended Operating September 30, activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net loss $ (135,128 ) $ (190,862 ) Adjustments to reconcile net loss to net cash used in operating activities Stock-based 154,901 79,408 compensation Gain on marketable (108,939 ) (4,731 ) equity securities Loss on disposal of property and 375 — equipment Deferred income — (46,216 ) taxes Losses from equity 8,318 2,465 method investments Amortization of original issue 5,008 2,615 discount Amortization of deferred financing 260 398 fees Change in fair value of holdback 1,189 291 liability Loss on debt 11,643 12,034 extinguishment Depreciation and 78,392 75,416 amortization Provision for bad 2,450 767 debt expense Provision for 111 1,135 obsolete inventory Non-cash operating 10,296 7,866 lease costs Minimum accretion 97 109 expense PIK interest added 1,674 8,839 to principal Change in assets and liabilities Accounts (71,839 ) (63,199 ) receivable(1) Inventory (2,160 ) (6,537 ) Prepaid expenses and other current (6,997 ) (3,991 ) assets Investments and 1,883 (16,700 ) other assets Accounts payable (49,250 ) (18,528 ) Related party 7,292 (25,000 ) asset Deferred (24,107 ) 17,398 revenue(2) Deferred other (11,966 ) (11,966 ) income(3) Accrued data (3,180 ) 3,730 licensing fees Accrued expenses & 58,493 (5,179 ) other Interest payable 10,360 10,288 Operating lease (10,762 ) (11,152 ) liabilities Net cash used in operating $ (71,586 ) $ (181,302 ) activities

(1) Includes increase in related party accounts receivable from Pathos AI, Inc. of $5,664 and $2,352 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 16, Related Parties. Includes increase in related party accounts receivable from SB Tempus Corp. of $145 and $108 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 7, Joint Venture. (2) Includes decrease in related party deferred revenue from Pathos AI, Inc. of $3,835 for the nine months ended September 30, 2026. Includes increase in related party deferred revenue from Pathos AI, Inc. of $19,918 for the nine months ended September 30, 2025, respectively. Refer to Note 16, Related Parties. Also includes decrease in related party deferred revenue from SB Tempus Corp. of $6,235 and $18,737 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 7, Joint Venture. (3) Includes decrease in related party deferred other income from SB Tempus Corp. of $11,966 for each of the nine months ended September 30, 2026 and 2025. Refer to Note 7, Joint Venture.

Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)

Nine Months Ended Investing September 30, activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Purchases of property and $ (23,665 ) $ (16,294 ) equipment Proceeds from sale of marketable — 8,316 equity securities Business combinations, net (2,763 ) (375,025 ) of cash acquired (Note 4) Capitalized (12,252 ) (4,635 ) software costs Net cash used in investing $ (38,680 ) $ (387,638 ) activities Financing activities Proceeds from convertible senior notes, 443,132 726,497 net of initial purchasers' discount Principal payments (207,717 ) (276,892 ) on long-term debt Principal payments on revolving (100,000 ) — credit facility Prepayment premium (6,433 ) (7,841 ) on long-term debt Payment of deferred offering (264 ) (501 ) costs Purchases of (31,234 ) (41,775 ) capped call Proceeds from revolving credit facility, — 98,000 net of original issue discount Proceeds from long-term debt, net of — 196,000 original issue discount Proceeds from issuance of common stock in connection with — 195,499 at-the-market offering, net of commissions Payment of deferred financing (1,349 ) (1,255 ) fees Net cash provided by financing $ 96,135 $ 887,732 activities Effect of foreign exchange rates on $ (86 ) $ (78 ) cash Net (decrease) increase in Cash, Cash $ (14,217 ) $ 318,714 Equivalents and Restricted Cash Cash, cash equivalents and restricted 609,451 341,835 cash, beginning of period Cash, cash equivalents and restricted $ 595,234 $ 660,549 cash, end of period Cash, Cash Equivalents and Restricted Cash are Comprised of:

Cash and cash $ 590,479 $ 655,918 equivalents Restricted cash and cash 4,755 4,631 equivalents Total cash, cash equivalents and $ 595,234 $ 660,549 restricted cash Supplemental disclosure of cash flow information Cash paid during the year for $ 15,111 $ 37,349 interest Cash paid for $ 246 $ 573 income taxes Preferred stock received on $ 17,500 $ — accounts receivable(4)

(4) Includes related party preferred stock of Pathos AI, Inc. of $17,500 for the nine months ended September 30, 2026.

Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)

Supplemental disclosure of noncash Nine Months Ended investing and financing September 30, activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Purchases of property and equipment, $ 10,226 $ 3,724 accrued but not paid Redemption of convertible promissory $ 32,705 $ 22,721 note Deferred financing fees, accrued but not $ — $ 489 yet paid Deferred offering costs, accrued but not $ 71 $ 320 yet paid Reclassification of deferred offering costs to additional $ — $ 821 paid-in capital upon at-the-market offering Operating lease liabilities arising from $ 360 $ 22,670 obtaining right-of-use assets Capitalized software costs, accrued but $ 21,536 $ — not yet paid Class A Common Stock issued in $ 13,319 $ 403,154 connection with business combinations Class A Common Stock issued in $ — $ 1,443 connection with license agreement Class A Common Stock issued in $ 6,173 $ — connection with holdback liability Convertible promissory note principal $ — $ 72,488 reset due to amendment

Tempus AI, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (in thousands, except percentages and per share amounts) Diagnostics Gross Profit & Gross Margin

(1) Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions during the three and nine months ended September 30, 2026 and 2025. Loss from Operations

(1) Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions during the three and nine months ended September 30, 2026 and 2025.

(1) Fair value changes include gains and losses related to quarterly fair value adjustments of our marketable equity securities and indemnity-related holdback liabilities. (2) Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions during the three and nine months ended September 30, 2026 and 2025. Adjusted EBITDA

(1) Fair value changes include gains and losses related to quarterly fair value adjustments of our marketable equity securities and indemnity-related holdback liabilities. (2) Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions during the three and nine months ended September 30, 2026 and 2025.

Full text with the tables
                                                                    Exhibit 99.1
                   Tempus Reports Third Quarter 2026 Results                    
CHICAGO, November 2, 2026— Tempus AI, Inc. (NASDAQ: TEM), a technology company  
leading the adoption of AI to advance precision medicine, today reported        
financial results for the quarter ended September 30, 2026.                     
                                                                                
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led  
by accelerating unit growth of 32% in our oncology business and increasing      
momentum of 33% revenue growth in Data & Applications,” said Eric Lefkofsky,    
founder and CEO of Tempus. “These results reinforce the durability of our model 
as our best-in-class diagnostic platform enhances our data and AI offerings,    
distinguishes our business from our many competitors, and helps drive our       
performance quarter after quarter.”                                             
                                                                                
Third Quarter 2026 Highlights                                                   
                                                                                
For the three-month period ended September 30, 2026, as compared to the same    
period in 2025:                                                                 
                                                                                
• Total revenue of $411.5 million, an increase of 23%                           
                                                                                
• Oncology volume growth accelerated to 32%                                     
                                                                                
• Minimal Residual Disease (MRD) volume of ~12,000 tests, up 300%               
                                                                                
• Data & Apps revenue increased 33%, with Insights increasing 29%               
                                                                                
• Increasing full year 2026 revenue guidance to $1.60 to $1.605 billion and     
expect full year Adjusted EBITDA of ~$65 million                                
                                                                                
• Announced multi-year strategic collaboration with Merck and Moderna to support
commercialization of their individualized neoantigen therapy (INT) class of     
drugs                                                                           
                                                                                
• In October, announced a strategic collaboration with BMS bringing Tempus’     
total data licensing bookings to >$550 million year to date                     
                                                                                
Third Quarter 2026 Summary Results                                              
                                                                                
For the three-month period ended September 30, 2026, as compared to the same    
period in 2025:                                                                 
                                                                                
• Total revenue increased 23% to $411.5 million.                                
                                                                                
• Diagnostics generated $303.5 million of revenue, representing 20% growth,     
driven by Oncology volume growth of 32%, offset by Hereditary revenue growth of 
3%.                                                                             
                                                                                
• Data and Applications generated $108.1 million of revenue, representing 33%   
growth, with Insights growing 29%.                                              
                                                                                
• Gross profit increased 27% to $266.7 million, led by growth in Data and       
Applications.                                                                   
                                                                                
• Net loss was $(14.9) million, which included $50.8 million of stock-based     
compensation expense and related employer payroll taxes and $42.8 million in    
unrealized gains on marketable securities, compared to a net loss of $(80.0)    
million in Q3 of 2025.                                                          
                                                                                
• Adjusted EBITDA was $25.6 million, compared to $1.5 million in Q3 of 2025.    
                                                                                
• Ended the quarter with cash and marketable securities of $854.4 million.      
                                                                                
Detailed Operational Highlights                                                 
                                                                                
• Announced a strategic collaboration with BMS in October through which Tempus  
is directly licensing to BMS oncology data and models for up to $137.5 million  
over a five-year term. In addition, BMS and Pathos are licensing data for       
patients with Alzheimer's or dementia for $55 million over a five-year term,    
extending Tempus’ data and modeling platform beyond oncology.                   
                                                                                
• Announced a multi-year strategic collaboration with Merck and Moderna to      
support the potential commercialization of intismeran autogene, a novel,        
potential first-in-class individualized neoantigen therapy (INT) being evaluated
in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in     
patients with completed resected stage IIB-IV melanoma and other cancer types.  
• Cleared regulatory review of pending acquisition of Personalis (Nasdaq: PSNL).
Personalis' shareholder meeting to approve the acquisition is planned for
November 30, 2026. • Received two 510(k) clearances from the U.S. Food and Drug
Administration (FDA) for Tempus ECG-PH and ECG-MR, expanding our non-invasive AI
cardiology footprint. • Announced an initiative to build a research platform
containing 100,000 whole genomes linked to longitudinal clinical information
over the next several years. Third Quarter Financial Results
                                                                                
                Three                                                           
                Months                                                          
                Ended                                                           
                September                                                       
                30,                                                             
                2026                                                            
                (in                                                             
                thousands,                                                      
                except                                                          
                percentag…                                                      
                and per                                                         
                share                                                           
                amounts)                                                        
                (unaudite…                2025                Change            
 ────────────────────────────────────────────────────────────────────────────── 
  Revenue       $           411,537       $     334,206                  23  %  
  Gross         $           266,701       $     209,942                  27  %  
  profit                                                                        
  Loss from     $           (56,864  )    $     (60,996  )                7  %  
  operations                                                                    
  Non-GAAP                                                                      
  income                                                                        
  (loss)        $            14,422       $      (8,662  )              267  %  
  from                                                                          
  operations                                                                    
  Net loss      $           (14,851  )    $     (79,982  )               81  %  
  Non-GAAP                                                                      
  net income    $            13,359       $     (19,590  )              168  %  
  (loss)                                                                        
  Adjusted      $            25,572       $       1,476               1,633  %  
  EBITDA                                                                        
  Net loss                                                                      
  per share,    $             (0.08  )    $       (0.46  )               83  %  
  basic and                                                                     
  diluted                                                                       
  Non-GAAP                                                                      
  net income                                                                    
  (loss) per    $              0.07       $       (0.11  )              164  %  
  share,                                                                        
  basic and                                                                     
  diluted                                                                       
                                                                                
Financial Outlook and Guidance Tempus is increasing its full year 2026 revenue
guidance to $1.60 to $1.605 billion, which represents ~25% annual growth. We
continue to expect 2026 Adjusted EBITDA to be ~$65 million. For additional
information on the quarter, including a letter from our CEO and CFO, please
visit our investor relations site at investors.tempus.com. Webcast and
Conference Call Information A conference call and webcast will begin today,
November 2, 2026 at 8:45 a.m. Eastern Time. Interested parties may access
details at: Conference ID: 579 261 752 United States (Toll-Free): (833) 461-5787
International (Toll): +1 (585) 542-9983 Live webcast can be accessed here The
webcast may be accessed on the company’s investor relations website at
investors.tempus.com. For those unable to listen to the live webcast, a
recording will be made available on the company’s website after the event and
will be accessible for one year. Visit the investor relations website to find
the company’s latest deck, and commentary on the quarter by Eric Lefkofsky,
Founder and CEO, and Jim Rogers, CFO, which will be discussed on the conference
call and webcast. About Tempus Tempus is a technology company making precision
medicine a reality through the practical application of artificial intelligence
in healthcare. With one of the world’s largest libraries of de-identified
multimodal data and an intelligent operating system that makes that data
accessible and actionable, Tempus connects AI, diagnostics and clinical
workflows to deliver more personalized patient care and accelerate the
discovery, development and delivery of better medicines. By continuously
transforming data into insights, Tempus
is building a learning healthcare ecosystem in which every patient can benefit  
from the treatment and experiences of those who came before.                    
                                                                                
For more information, visittempus.comand follow Tempus onLinkedIn,Instagram,    
andX.                                                                           
                                                                                
Non-GAAP Financial Measures                                                     
                                                                                
In addition to the financial information presented in this release in accordance
with accounting principles generally accepted in the United States of America   
(GAAP), Tempus also presents adjusted non-GAAP financial measures.              
                                                                                
Non-GAAP gross profitis defined as GAAP gross profit, excluding stock-based     
compensation expense and employer payroll tax related to stock-based            
compensation (collectively, the “stock-based compensation adjustments”).Non-GAAP
gross marginis defined as gross profit, excluding the stock-based compensation  
adjustments, as a percentage of revenue.Non-GAAP operating expensesare          
calculated as the sum of technology research and development expense, research  
and development expense, and selling, general and administrative expense,       
excluding the stock-based compensation adjustments, acquisition-related         
expenses, amortization of intangibles due to acquisition, and franchise taxes   
related to IPO.Non-GAAP income (loss) from operationsis defined as loss from    
operations, adjusted to exclude (i) the stock-based compensation adjustments,   
(ii) acquisition-related expenses, (iii) franchise taxes related to IPO, and    
(iv) amortization of intangibles due to acquisition.Non-GAAP net income (loss)is
defined as net loss, adjusted to exclude (i) changes in fair value of our       
marketable equity securities and indemnity-related holdback liabilities, (ii)   
the stock-based compensation adjustments, (iii) acquisition-related expenses,   
(iv) amortization of intangibles due to acquisition, (v) losses (gains) from    
equity method investments, (vi) provision for (benefit from) income taxes, (vii)
franchise taxes related to IPO, (viii) amortization of deferred other income    
from our IP License Agreement with SB Tempus, and (ix) loss on debt             
extinguishment.Non-GAAP net income (loss) per shareis defined as non-GAAP net   
income (loss) divided by weighted average common shares outstanding, basic and  
diluted.                                                                        
                                                                                
Adjusted EBITDAis defined as net loss, adjusted to exclude (i) interest income, 
(ii) interest expense, (iii) depreciation and amortization, (iv) provision for  
(benefit from) income taxes, (v) losses (gains) from equity method investments, 
(vi) changes in fair value of our marketable equity securities and indemnity-   
related holdback liabilities, (vii) the stock-based compensation adjustments,   
(viii)acquisition-related expenses, (ix) amortization of deferred other income  
from our IP License Agreement with SB Tempus, (x) franchise taxes related to our
IPO, and (xi) loss on debt extinguishment.                                      
                                                                                
Tempus believes these non-GAAP financial measures are useful to investors and   
others because they allow for additional information with respect to financial  
measures used by management in its financial and operational decision-making and
they may be used by institutional investors and the analyst community to help   
them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a
key measurement used by Tempus management to make operating decisions, including
those related to analyzing operating expenses, evaluating performance, and      
performing strategic planning and annual budgeting. However, there are a number 
of limitations related to the use of non-GAAP financial measures, and these non-
GAAP measures should be considered in addition to, not as a substitute for or in
isolation from, our financial results prepared in accordance with GAAP. Other   
companies, including companies in our industry, may calculate these non-GAAP    
financial measures differently or not at all, which reduces their usefulness as 
comparative measures.                                                           
                                                                                
Tempus does not provide guidance for net loss, the most directly comparable GAAP
measure to Adjusted EBITDA, and similarly cannot provide a reconciliation       
between Tempus’ forecasted Adjusted EBITDA and net loss without unreasonable    
effort due to the unavailability of reliable estimates for certain components of
net loss and the respective reconciliations. These forecasted items are not     
within Tempus’ control, may vary greatly between periods, and could             
significantly impact future financial results.                                  
                                                                                
Forward Looking Statements                                                      
                                                                                
This press release contains forward-looking statements within the meaning of    
Section 27A of the Securities Act of 1933, as amended (the “Securities Act”),and
Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and
its industry that involve substantial risks and uncertainties. All statements   
other than statements of historical facts contained in this press release are   
forward-looking statements, including, but not limited to, Tempus’ expected     
financial results for full year 2026; expectations concerning Tempus'           
collaborations and partnerships; Tempus' competitive position; and the pending  
acquisition of Personalis. In some cases, you can identify forward-looking      
statements because they contain words such as “anticipate,” “believe,”          
“contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” 
“may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or
“would” or the negative of these words or other similar terms or expressions.   
Tempus cautions you that the foregoing may not include all of the forward-      
looking statements made in this press release.                                  
                                                                                
You should not rely on forward-looking statements as predictions of future      
events. Tempus has based the forward-looking statements contained in this press 
release primarily on its current expectations and projections about future      
events and trends that it believes may                                          
                                                                                
affect Tempus’ business, financial condition, results of operations and         
prospects. These forward-looking statements are subject to risks and            
uncertainties related to: the intended use of Tempus’ products and services;    
Tempus’ financial performance; the ability to attract and retain customers and  
partners; managing Tempus’ growth and future expenses; competition and new      
market entrants; compliance with new laws, regulations and executive actions,   
including any evolving regulations in the artificial intelligence space; the    
ability to maintain, protect and enhance Tempus’ intellectual property; the     
ability to attract and retain qualified team members and key personnel; the     
ability to repay or refinance outstanding debt, or to access additional         
financing; future acquisitions, divestitures or investments, including Tempus'  
ability to consummate the acquisition of Personalis on the contemplated terms or
at all and Tempus’ ability to realize the expected benefits of the acquisition  
of Paige AI, Ambry Genetics, Deep 6 AI, Center Health, and, if consummated,     
Personalis; the potential adverse impact of climate change, natural disasters,  
health epidemics, macroeconomic conditions, and war or other armed conflict, as 
well as risks, uncertainties, and other factors described in the section titled 
“Risk Factors” in Tempus’ Form 10-K for the year ended December 31, 2025, filed 
with the Securities and Exchange Commission (the "SEC") on February 24, 2026, as
well as in other filings Tempus may make with the SEC from time to time. In     
addition, any forward-looking statements contained in this press release are    
based on assumptions that Tempus believes to be reasonable as of this date.     
Tempus undertakes no obligation to update any forward-looking statements to     
reflect events or circumstances after the date of this press release or to      
reflect new information or the occurrence of unanticipated events, except as    
required by law.                                                                
                                                                                
Investors                                                                       
                                                                                
Kendra Webster                                                                  
                                                                                
[email protected]                                                    
                                                                                
Media                                                                           
                                                                                
Kelli Manalli                                                                   
                                                                                
[email protected]                                                        
                                                                                
Source: Tempus AI, Inc.                                                         
Tempus AI, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS (Unaudited) (in thousands, except per share amounts)
                                                                                
          Three                                Nine                             
          Mont…                                Mon…                             
          Ended                                End…                             
          Sept…                                Sep…                             
  Net     30,                                  30,                              
  rev…    2026               2025              2026              2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Dia…    $      303,…       $     252,…       $     853,…       $     688…     
  Data                                                                          
  and            108,…             81,3…             288,…             216…     
  app…                                                                          
  Tot…                                                                          
  net     $      411,…       $     334,…       $     1,14…       $     904…     
  rev…                                                                          
  Cost                                                                          
  and                                                                           
  ope…                                                                          
  exp…                                                                          
  Cost                                                                          
  of             114,…             98,6…             323,…             283…     
  rev…                                                                          
  dia…                                                                          
  Cost                                                                          
  of                                                                            
  rev…           30,7…             25,6…             83,6…             61,…     
  data                                                                          
  and                                                                           
  app…                                                                          
  Tec…                                                                          
  res…           45,7…             38,0…             135,…             105…     
  and                                                                           
  dev…                                                                          
  Res…                                                                          
  and            46,0…             44,9…             146,…             122…     
  dev…                                                                          
  Sel…                                                                          
  gen…           231,…             187,…             670,…             523…     
  and                                                                           
  adm…                                                                          
  Tot…                                                                          
  cost                                                                          
  and            468,…             395,…             1,35…             1,0…     
  ope…                                                                          
  exp…                                                                          
  Loss                                                                          
  from    $      (56,…  )    $     (60,…  )    $     (217…  )    $     (19…  )  
  ope…                                                                          
  Int…           3,985             4,600             11,7…             7,5…     
  inc…                                                                          
  Int…           (6,7…  )          (15,…  )          (31,…  )          (54…  )  
  exp…                                                                          
  Loss                                                                          
  on                 —             (12,…  )          (11,…  )          (12…  )  
  debt                                                                          
  ext…                                                                          
  Oth…                                                                          
  inc…           47,1…             2,605             122,…             16,…     
  net…                                                                          
  Loss                                                                          
  bef…                                                                          
  (pr…                                                                          
  for)    $      (12,…  )    $     (81,…  )    $     (126…  )    $     (23…  )  
  ben…                                                                          
  from                                                                          
  inc…                                                                          
  tax…                                                                          
  (Pr…                                                                          
  for)                                                                          
  ben…             (35  )           (276  )           (282  )          45,…     
  from                                                                          
  inc…                                                                          
  tax…                                                                          
  (Lo…                                                                          
  gai…                                                                          
  from           (2,3…  )          1,518             (8,3…  )          (2,…  )  
  equ…                                                                          
  met…                                                                          
  inv…                                                                          
  Net     $      (14,…  )    $     (79,…  )    $     (135…  )    $     (19…  )  
  loss                                                                          
  Net                                                                           
  loss                                                                          
  per                                                                           
  sha…    $      (0.08  )    $     (0.46  )    $     (0.75  )    $     (1.…  )  
  bas…                                                                          
  and                                                                           
  dil…                                                                          
  Wei…                                                                          
  sha…                                                                          
  out…                                                                          
  used                                                                          
  to                                                                            
  com…                                                                          
  net            181,…             174,…             180,…             172…     
  loss                                                                          
  per                                                                           
  sha…                                                                          
  bas…                                                                          
  and                                                                           
  dil…                                                                          
  Com…                                                                          
  los…                                                                          
  net                                                                           
  of                                                                            
  tax                                                                           
  Net     $      (14,…  )    $     (79,…  )    $     (135…  )    $     (19…  )  
  loss                                                                          
  For…                                                                          
  cur…           2,107             (2,9…  )           (736  )          5,4…     
  tra…                                                                          
  adj…                                                                          
  Com…    $      (12,…  )    $     (82,…  )    $     (135…  )    $     (18…  )  
  loss                                                                          
                                                                                
(1) Includes related party revenue from Pathos AI, Inc. of $0 and $225 for the
three months ended September 30, 2026 and 2025, respectively. Includes related
party revenue from Pathos AI, Inc. of $190 and $226 for the nine months ended
September 30, 2026 and 2025, respectively. Refer to Note 16, Related Parties.
(2) Includes related party revenue from Pathos AI, Inc. of $22,061 and $24,907
for the three months ended September 30, 2026 and 2025, respectively. Includes
related party revenue from Pathos AI, Inc. of $65,718 and $41,445 for the nine
months ended September 30, 2026 and 2025, respectively. Refer to Note 16,
Related Parties. Also includes related party revenue from SB Tempus Corp. of $0
and $6,253 for the three months ended September 30, 2026 and 2025, respectively.
Includes related party revenue from SB Tempus Corp. of $6,241 and $18,743 for
the nine months ended September 30, 2026 and 2025, respectively. Refer to Note
7, Joint Venture. (3) Includes related party other income from SB Tempus Corp.
of $3,989 for each of the three months ended September 30, 2026 and 2025.
Includes related party other income from SB Tempus Corp. of $11,966 for each of
the nine months ended September 30, 2026 and 2025. Refer to Note 7, Joint
Venture.

Tempus AI, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands,
except share and per share amounts)
                                                                                
                                    September 30, 2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current Assets                                                                
  Cash and cash equivalents      $             590,479    $            604,787  
  Accounts receivable(1), net                                                   
  of                                                                            
  allowances of $4,378 and                                                      
  $2,755 at                                    380,744                 311,170  
  September 30, 2026 and                                                        
  December 31,                                                                  
  2025, respectively                                                            
  Inventory                                     53,773                  51,724  
  Related party asset                           17,500                   8,785  
  Prepaid expenses and other                                                    
  current                                       47,507                  40,498  
  assets                                                                        
  Marketable equity                             46,874                 150,211  
  securities                                                                    
  Total current assets           $           1,136,877    $          1,167,175  
  Property and equipment, net                   95,186                  89,156  
  Goodwill                                     488,142                 470,211  
  Intangible assets, net                       293,815                 349,202  
  Capitalized software, net                     40,561                   6,051  
  Marketable equity                                                             
  securities, less                             212,276                       —  
  current portion                                                               
  Investments and other                         16,241                  21,111  
  assets                                                                        
  Investment in joint venture                   77,635                  86,557  
  Investment in related party                   17,500                       —  
  Related party asset, less                                                     
  current                                       10,208                  16,215  
  portion                                                                       
  Operating lease                               58,402                  64,496  
  right-of-use assets                                                           
  Restricted cash                                4,755                   4,664  
  Total Assets                   $           2,451,598    $          2,274,838  
  Liabilities, Convertible                                                      
  redeemable                                                                    
  preferred stock, and                                                          
  Stockholders'                                                                 
  equity                                                                        
  Current Liabilities                                                           
  Accounts payable                              70,506                  81,994  
  Related party payable                         10,000                       —  
  Accrued expenses                             232,976                 155,370  
  Deferred revenue(2)                           85,931                  92,673  
  Deferred other income(3)                      11,966                  15,955  
  Other current liabilities                     12,146                   8,680  
  Operating lease liabilities                   11,584                  13,355  
  Accrued data licensing fees                    1,296                   4,361  
  Total current liabilities      $             436,405    $            372,388  
                                                                                
(1) Includes related party accounts receivable from Pathos AI, Inc. of $12,092
and $6,428 as of September 30, 2026 and December 31, 2025, respectively. Refer
to Note 16, Related Parties. Also includes related party accounts receivable
from SB Tempus Corp. of $318 and $173 as of September 30, 2026 and December 31,
2025, respectively. Refer to Note 7, Joint Venture. (2) Includes related party
deferred revenue from Pathos AI, Inc. of $103 and $3,938 as of September 30,
2026 and December 31, 2025, respectively. Refer to Note 16, Related Parties.
Also includes related party deferred revenue from SB Tempus Corp. of $0 and
$6,235 as of September 30, 2026 and December 31, 2025, respectively. Refer to
Note 7, Joint Venture. (3) Deferred other income balances solely related to SB
Tempus Corp. Refer to Note 7, Joint Venture.

Tempus AI, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands,
except share and per share amounts)
                                                                                
                              September 30, 2026          December 31, 2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Operating lease                                                               
  liabilities, less                       69,483                     74,272     
  current portion                                                               
  Convertible                            175,967                    208,672     
  promissory note                                                               
  Other long-term                         51,449                     56,600     
  liabilities                                                                   
  Revolving credit                             —                    100,000     
  facility                                                                      
  Interest payable                        22,501                     12,393     
  Long-term debt, net                          —                    202,753     
  Convertible senior                   1,174,877                    728,078     
  notes, net                                                                    
  Deferred other                                                                
  income, less current                         —                      7,977     
  portion(3)                                                                    
  Deferred revenue,                       20,514                     20,379     
  less current portion                                                          
  Total Liabilities        $           1,951,196       $          1,783,512     
  Commitments and                                                               
  contingencies (Note                                                           
  8)                                                                            
  Convertible                                                                   
  redeemable preferred                                                          
  stock,                                                                        
  $0.0001 par value,                                                            
  20,000,000 shares                                                             
  authorized at                                                                 
  September 30, 2026       $                   —       $                  —     
  and                                                                           
  December 31, 2025,                                                            
  respectively, no                                                              
  shares outstanding at                                                         
  September 30, 2026                                                            
  and December 31, 2025                                                         
  Stockholders' equity                                                          
  Class A Common Stock,                                                         
  $0.0001 par value,                                                            
  1,000,000,000 shares                                                          
  authorized at                                                                 
  September 30, 2026                                                            
  and December 31,                                                              
  2025, respectively;                         18                         17     
  177,182,062 and                                                               
  173,235,428 shares                                                            
  outstanding at                                                                
  September 30, 2026                                                            
  and December 31,                                                              
  2025, respectively                                                            
  Class B Common Stock,                                                         
  $0.0001 par value,                                                            
  5,500,000 shares                                                              
  authorized at                                                                 
  September                                                                     
  30, 2026 and December                                                         
  31, 2025,                                    1                          1     
  respectively;                                                                 
  5,043,789 outstanding                                                         
  at                                                                            
  September 30, 2026                                                            
  and December 31,                                                              
  2025, respectively                                                            
  Treasury Stock,                                                               
  203,431 and 183,229                                                           
  shares at September                     (6,642  )                  (6,642  )  
  30, 2026 and                                                                  
  December 31, 2025,                                                            
  respectively, at cost                                                         
  Additional paid-in                   3,037,849                  2,892,910     
  capital                                                                       
  Accumulated other                          166                        902     
  comprehensive income                                                          
  Accumulated deficit                 (2,530,990  )              (2,395,862  )  
  Total Stockholders'      $             500,402       $            491,326     
  equity                                                                        
  Total Liabilities,                                                            
  Convertible                                                                   
  redeemable preferred     $           2,451,598       $          2,274,838     
  stock, and                                                                    
  Stockholders' equity                                                          
                                                                                
(3) Deferred other income balances solely related to SB Tempus Corp. Refer to
Note 7, Joint Venture.

Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in
thousands)
                                                                                
                        Nine Months Ended                                       
  Operating             September 30,                                           
  activities            2026                                 2025               
 ────────────────────────────────────────────────────────────────────────────── 
  Net loss              $                     (135,128  )    $     (190,862  )  
  Adjustments to                                                                
  reconcile net loss                                                            
  to net                                                                        
  cash used in                                                                  
  operating                                                                     
  activities                                                                    
  Stock-based                                  154,901               79,408     
  compensation                                                                  
  Gain on marketable                          (108,939  )            (4,731  )  
  equity securities                                                             
  Loss on disposal                                                              
  of property and                                  375                    —     
  equipment                                                                     
  Deferred income                                    —              (46,216  )  
  taxes                                                                         
  Losses from equity                             8,318                2,465     
  method investments                                                            
  Amortization of                                                               
  original issue                                 5,008                2,615     
  discount                                                                      
  Amortization of                                                               
  deferred financing                               260                  398     
  fees                                                                          
  Change in fair                                                                
  value of holdback                              1,189                  291     
  liability                                                                     
  Loss on debt                                  11,643               12,034     
  extinguishment                                                                
  Depreciation and                              78,392               75,416     
  amortization                                                                  
  Provision for bad                              2,450                  767     
  debt expense                                                                  
  Provision for                                    111                1,135     
  obsolete inventory                                                            
  Non-cash operating                            10,296                7,866     
  lease costs                                                                   
  Minimum accretion                                 97                  109     
  expense                                                                       
  PIK interest added                             1,674                8,839     
  to principal                                                                  
  Change in assets                                                              
  and liabilities                                                               
  Accounts                                     (71,839  )           (63,199  )  
  receivable(1)                                                                 
  Inventory                                     (2,160  )            (6,537  )  
  Prepaid expenses                                                              
  and other current                             (6,997  )            (3,991  )  
  assets                                                                        
  Investments and                                1,883              (16,700  )  
  other assets                                                                  
  Accounts payable                             (49,250  )           (18,528  )  
  Related party                                  7,292              (25,000  )  
  asset                                                                         
  Deferred                                     (24,107  )            17,398     
  revenue(2)                                                                    
  Deferred other                               (11,966  )           (11,966  )  
  income(3)                                                                     
  Accrued data                                  (3,180  )             3,730     
  licensing fees                                                                
  Accrued expenses &                            58,493               (5,179  )  
  other                                                                         
  Interest payable                              10,360               10,288     
  Operating lease                              (10,762  )           (11,152  )  
  liabilities                                                                   
  Net cash used in                                                              
  operating             $                      (71,586  )    $     (181,302  )  
  activities                                                                    
                                                                                
(1) Includes increase in related party accounts receivable from Pathos AI, Inc.
of $5,664 and $2,352 for the nine months ended September 30, 2026 and 2025,
respectively. Refer to Note 16, Related Parties. Includes increase in related
party accounts receivable from SB Tempus Corp. of $145 and $108 for the nine
months ended September 30, 2026 and 2025, respectively. Refer to Note 7, Joint
Venture. (2) Includes decrease in related party deferred revenue from Pathos AI,
Inc. of $3,835 for the nine months ended September 30, 2026. Includes increase
in related party deferred revenue from Pathos AI, Inc. of $19,918 for the nine
months ended September 30, 2025, respectively. Refer to Note 16, Related
Parties. Also includes decrease in related party deferred revenue from SB Tempus
Corp. of $6,235 and $18,737 for the nine months ended September 30, 2026 and
2025, respectively. Refer to Note 7, Joint Venture. (3) Includes decrease in
related party deferred other income from SB Tempus Corp. of $11,966 for each of
the nine months ended September 30, 2026 and 2025. Refer to Note 7, Joint
Venture.

Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in
thousands)
                                                                                
                        Nine Months Ended                                       
  Investing             September 30,                                           
  activities            2026                                 2025               
 ────────────────────────────────────────────────────────────────────────────── 
  Purchases of                                                                  
  property and          $                      (23,665  )    $      (16,294  )  
  equipment                                                                     
  Proceeds from sale                                                            
  of marketable                                      —                8,316     
  equity                                                                        
  securities                                                                    
  Business                                                                      
  combinations, net                             (2,763  )          (375,025  )  
  of cash                                                                       
  acquired (Note 4)                                                             
  Capitalized                                  (12,252  )            (4,635  )  
  software costs                                                                
  Net cash used in                                                              
  investing             $                      (38,680  )    $     (387,638  )  
  activities                                                                    
  Financing                                                                     
  activities                                                                    
  Proceeds from                                                                 
  convertible senior                                                            
  notes,                                       443,132              726,497     
  net of initial                                                                
  purchasers'                                                                   
  discount                                                                      
  Principal payments                          (207,717  )          (276,892  )  
  on long-term debt                                                             
  Principal payments                                                            
  on revolving                                (100,000  )                 —     
  credit                                                                        
  facility                                                                      
  Prepayment premium                            (6,433  )            (7,841  )  
  on long-term debt                                                             
  Payment of                                                                    
  deferred offering                               (264  )              (501  )  
  costs                                                                         
  Purchases of                                 (31,234  )           (41,775  )  
  capped call                                                                   
  Proceeds from                                                                 
  revolving credit                                                              
  facility,                                          —               98,000     
  net of original                                                               
  issue discount                                                                
  Proceeds from                                                                 
  long-term debt,                                                               
  net of                                             —              196,000     
  original issue                                                                
  discount                                                                      
  Proceeds from                                                                 
  issuance of common                                                            
  stock                                                                         
  in connection with                                 —              195,499     
  at-the-market                                                                 
  offering, net of                                                              
  commissions                                                                   
  Payment of                                                                    
  deferred financing                            (1,349  )            (1,255  )  
  fees                                                                          
  Net cash provided                                                             
  by financing          $                       96,135       $      887,732     
  activities                                                                    
  Effect of foreign                                                             
  exchange rates on     $                          (86  )    $          (78  )  
  cash                                                                          
  Net (decrease)                                                                
  increase in Cash,                                                             
  Cash                  $                      (14,217  )    $      318,714     
  Equivalents and                                                               
  Restricted Cash                                                               
  Cash, cash                                                                    
  equivalents and                                                               
  restricted                                   609,451              341,835     
  cash, beginning of                                                            
  period                                                                        
  Cash, cash                                                                    
  equivalents and                                                               
  restricted            $                      595,234       $      660,549     
  cash, end of                                                                  
  period                                                                        
  Cash, Cash                                                                    
  Equivalents and                                                               
  Restricted                                                                    
  Cash are Comprised                                                            
  of:                                                                           
                                                                                
  Cash and cash         $                      590,479       $      655,918     
  equivalents                                                                   
  Restricted cash                                                               
  and cash                                       4,755                4,631     
  equivalents                                                                   
  Total cash, cash                                                              
  equivalents and       $                      595,234       $      660,549     
  restricted cash                                                               
  Supplemental                                                                  
  disclosure of cash                                                            
  flow                                                                          
  information                                                                   
  Cash paid during                                                              
  the year for          $                       15,111       $       37,349     
  interest                                                                      
  Cash paid for         $                          246       $          573     
  income taxes                                                                  
  Preferred stock                                                               
  received on           $                       17,500       $            —     
  accounts                                                                      
  receivable(4)                                                                 
                                                                                
(4) Includes related party preferred stock of Pathos AI, Inc. of $17,500 for the
nine months ended September 30, 2026.

Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in
thousands)
                                                                                
  Supplemental disclosure                                                       
  of noncash                 Nine Months Ended                                  
  investing and financing    September 30,                                      
  activities                 2026                                2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Purchases of property                                                         
  and equipment,             $                         10,226    $       3,724  
  accrued but not paid                                                          
  Redemption of                                                                 
  convertible promissory     $                         32,705    $      22,721  
  note                                                                          
  Deferred financing                                                            
  fees, accrued but not      $                              —    $         489  
  yet paid                                                                      
  Deferred offering                                                             
  costs, accrued but not     $                             71    $         320  
  yet paid                                                                      
  Reclassification of                                                           
  deferred offering                                                             
  costs to additional        $                              —    $         821  
  paid-in capital upon                                                          
  at-the-market offering                                                        
  Operating lease                                                               
  liabilities arising                                                           
  from                       $                            360    $      22,670  
  obtaining right-of-use                                                        
  assets                                                                        
  Capitalized software                                                          
  costs, accrued but         $                         21,536    $           —  
  not yet paid                                                                  
  Class A Common Stock                                                          
  issued in                  $                         13,319    $     403,154  
  connection with                                                               
  business combinations                                                         
  Class A Common Stock                                                          
  issued in                  $                              —    $       1,443  
  connection with license                                                       
  agreement                                                                     
  Class A Common Stock                                                          
  issued in                  $                          6,173    $           —  
  connection with                                                               
  holdback liability                                                            
  Convertible promissory                                                        
  note principal             $                              —    $      72,488  
  reset due to amendment                                                        
                                                                                
Tempus AI, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited) (in thousands, except percentages and per share amounts) Diagnostics
Gross Profit & Gross Margin
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Dia…    $     303,…       $     252,…       $     853,…       $     688,…     
  rev…                                                                          
  Cost                                                                          
  of            114,…             98,6…             323,…             283,…     
  rev…                                                                          
  dia…                                                                          
  Gro…                                                                          
  pro…    $     189,…       $     154,…       $     530,…       $     405,…     
  dia…                                                                          
  Sto…                                                                          
  com…          3,037             1,631             8,795             4,086     
  exp…                                                                          
  Emp…                                                                          
  pay…                                                                          
  tax                                                                           
  rel…            150                36               608               338     
  to                                                                            
  sto…                                                                          
  com…                                                                          
  Non…                                                                          
  gro…    $     192,…       $     155,…       $     540,…       $     409,…     
  pro…                                                                          
  dia…                                                                          
  Dia…                                                                          
  gro…           62.4  %           61.0  %           62.1  %           58.9  %  
  mar…                                                                          
  Sto…                                                                          
  com…            1.0  %            0.6  %            1.0  %            0.6  %  
  exp…                                                                          
  Emp…                                                                          
  pay…                                                                          
  tax                                                                           
  rel…            0.0  %            0.0  %            0.1  %            0.0  %  
  to                                                                            
  sto…                                                                          
  com…                                                                          
  Non…                                                                          
  gro…           63.5  %           61.7  %           63.2  %           59.5  %  
  mar…                                                                          
  dia…                                                                          
                                                                                
Data and applications Gross Profit & Gross Margin
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Data                                                                          
  and     $     108,…       $     81,3…       $     288,…       $     216,…     
  app…                                                                          
  rev…                                                                          
  Cost                                                                          
  of                                                                            
  rev…          30,7…             25,6…             83,6…             61,2…     
  data                                                                          
  and                                                                           
  app…                                                                          
  Gro…                                                                          
  pro…                                                                          
  data    $     77,2…       $     55,7…       $     204,…       $     154,…     
  and                                                                           
  app…                                                                          
  Sto…                                                                          
  com…          1,214               894             3,735             2,198     
  exp…                                                                          
  Emp…                                                                          
  pay…                                                                          
  tax                                                                           
  rel…             94                62               331               220     
  to                                                                            
  sto…                                                                          
  com…                                                                          
  Non…                                                                          
  gro…                                                                          
  pro…    $     78,5…       $     56,6…       $     208,…       $     157,…     
  data                                                                          
  and                                                                           
  app…                                                                          
  Gro…                                                                          
  mar…                                                                          
  data           71.5  %           68.5  %           71.0  %           71.7  %  
  and                                                                           
  app…                                                                          
  Sto…                                                                          
  com…            1.1  %            1.1  %            1.3  %            1.0  %  
  exp…                                                                          
  Emp…                                                                          
  pay…                                                                          
  tax                                                                           
  rel…            0.1  %            0.1  %            0.1  %            0.1  %  
  to                                                                            
  sto…                                                                          
  com…                                                                          
  Non…                                                                          
  gro…                                                                          
  mar…           72.7  %           69.7  %           72.4  %           72.8  %  
  data                                                                          
  and                                                                           
  app…                                                                          
                                                                                
Total Gross Profit & Gross Margin
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net     $     411,…       $     334,…       $     1,14…       $     904,…     
  rev…                                                                          
  Cost                                                                          
  of            144,…             124,…             406,…             344,…     
  rev…                                                                          
  Gro…    $     266,…       $     209,…       $     735,…       $     560,…     
  pro…                                                                          
  Sto…                                                                          
  com…          4,251             2,525             12,5…             6,284     
  exp…                                                                          
  Emp…                                                                          
  pay…                                                                          
  tax                                                                           
  rel…            245                98               940               558     
  to                                                                            
  sto…                                                                          
  com…                                                                          
  Non…                                                                          
  gro…    $     271,…       $     212,…       $     748,…       $     567,…     
  pro…                                                                          
  Gro…           64.8  %           62.8  %           64.4  %           61.9  %  
  mar…                                                                          
  Sto…                                                                          
  com…            1.0  %            0.8  %            1.1  %            0.7  %  
  exp…                                                                          
  Emp…                                                                          
  pay…                                                                          
  tax                                                                           
  rel…            0.1  %            0.0  %            0.1  %            0.1  %  
  to                                                                            
  sto…                                                                          
  com…                                                                          
  Non…                                                                          
  gro…           65.9  %           63.6  %           65.6  %           62.7  %  
  mar…                                                                          
                                                                                
Operating Expenses
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Techno…                                                                       
  resear…    $      45,708    $      38,087    $      135,558    $     105,960  
  and                                                                           
  develo…                                                                       
  Stock-…                                                                       
  compen…            7,954            5,463            26,101           12,067  
  expense                                                                       
  Employ…                                                                       
  payroll                                                                       
  tax                                                                           
  related              615              278             1,785            1,034  
  to                                                                            
  stock-…                                                                       
  compen…                                                                       
  Non-GA…                                                                       
  techno…                                                                       
  resear…    $      37,139    $      32,346    $      107,672    $      92,859  
  and                                                                           
  develo…                                                                       
  Resear…                                                                       
  and        $      46,000    $      44,960    $      146,874    $     122,453  
  develo…                                                                       
  Stock-…                                                                       
  compen…            5,432            3,301            15,284            7,618  
  expense                                                                       
  Employ…                                                                       
  payroll                                                                       
  tax                                                                           
  related              274              122             1,005              533  
  to                                                                            
  stock-…                                                                       
  compen…                                                                       
  Non-GA…                                                                       
  resear…    $      40,294    $      41,537    $      130,585    $     114,302  
  and                                                                           
  develo…                                                                       
  Sellin…                                                                       
  general    $     231,857    $     187,891    $      670,296    $     523,230  
  and                                                                           
  admini…                                                                       
  Stock-…                                                                       
  compen…           30,437           22,690           100,986           53,439  
  expense                                                                       
  Employ…                                                                       
  payroll                                                                       
  tax                                                                           
  related            1,615              541             4,071            6,040  
  to                                                                            
  stock-…                                                                       
  compen…                                                                       
  Acquis…                                                                       
  related            3,728              552             4,714            6,073  
  expens…                                                                       
  Amorti…                                                                       
  of                                                                            
  intang…           16,735           16,764            50,207           44,691  
  due to                                                                        
  acquis…                                                                       
  Franch…                                                                       
  taxes                  —                —                 —            1,647  
  related                                                                       
  to IPO                                                                        
  Non-GA…                                                                       
  sellin…                                                                       
  general    $     179,342    $     147,344    $      510,318    $     411,340  
  and                                                                           
  admini…                                                                       
  Operat…    $     323,565    $     270,938    $      952,728    $     751,643  
  expens…                                                                       
  Stock-…                                                                       
  compen…           43,823           31,454           142,371           73,124  
  expense                                                                       
  Employ…                                                                       
  payroll                                                                       
  tax                                                                           
  related            2,503              941             6,860            7,607  
  to                                                                            
  stock-…                                                                       
  compen…                                                                       
  Acquis…                                                                       
  related            3,728              552             4,714            6,073  
  expens…                                                                       
  Amorti…                                                                       
  of                                                                            
  intang…           16,735           16,764            50,207           44,691  
  due to                                                                        
  acquis…                                                                       
  Franch…                                                                       
  taxes                  —                —                 —            1,647  
  related                                                                       
  to IPO                                                                        
  Non-GA…                                                                       
  operat…    $     256,776    $     221,227    $      748,576    $     618,501  
  expens…                                                                       
                                                                                
(1) Acquisition related expenses consist of legal, diligence, accounting, and
financing costs incurred for acquisitions during the three and nine months ended
September 30, 2026 and 2025. Loss from Operations
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Loss                                                                          
  from    $     (56,…  )    $     (60,…  )    $     (217…  )    $     (191…  )  
  ope…                                                                          
  Sto…                                                                          
  com…          48,0…             33,9…             154,…             79,4…     
  exp…                                                                          
  Emp…                                                                          
  pay…                                                                          
  tax                                                                           
  rel…          2,749             1,039             7,800             8,165     
  to                                                                            
  sto…                                                                          
  com…                                                                          
  Acq…                                                                          
  rel…          3,728               552             4,714             6,073     
  exp…                                                                          
  Fra…                                                                          
  tax…                                                                          
  rel…              —                 —                 —             1,647     
  to                                                                            
  IPO                                                                           
  Amo…                                                                          
  of                                                                            
  int…          16,7…             16,7…             50,2…             44,6…     
  due                                                                           
  to                                                                            
  acq…                                                                          
  Non…                                                                          
  inc…                                                                          
  (lo…    $     14,4…       $     (8,6…  )    $       134       $     (51,…  )  
  from                                                                          
  ope…                                                                          
                                                                                
(1) Acquisition related expenses consist of legal, diligence, accounting, and
financing costs incurred for acquisitions during the three and nine months ended
September 30, 2026 and 2025.

Earnings per Share
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net     $     (14,…  )    $     (79,…  )    $     (135…  )    $     (190…  )  
  loss                                                                          
  Fair                                                                          
  val…          (41,…  )          1,255             (107…  )          (4,4…  )  
  cha…                                                                          
  Sto…                                                                          
  com…          48,0…             33,9…             154,…             79,4…     
  exp…                                                                          
  Emp…                                                                          
  pay…                                                                          
  tax                                                                           
  rel…          2,749             1,039             7,800             8,165     
  to                                                                            
  sto…                                                                          
  com…                                                                          
  Acq…                                                                          
  rel…          3,728               552             4,714             6,073     
  exp…                                                                          
  Amo…                                                                          
  of                                                                            
  int…          16,7…             16,7…             50,2…             44,6…     
  due                                                                           
  to                                                                            
  acq…                                                                          
  Los…                                                                          
  (ga…                                                                          
  from          2,368             (1,5…  )          8,318             2,465     
  equ…                                                                          
  met…                                                                          
  inv…                                                                          
  Pro…                                                                          
  for                                                                           
  (be…             35               276               282             (45,…  )  
  fro…                                                                          
  inc…                                                                          
  tax…                                                                          
  Fra…                                                                          
  tax…                                                                          
  rel…              —                 —                 —             1,647     
  to                                                                            
  IPO                                                                           
  Amo…                                                                          
  of            (3,9…  )          (3,9…  )          (11,…  )          (11,…  )  
  tec…                                                                          
  lic…                                                                          
  Loss                                                                          
  on                —             12,0…             11,6…             12,0…     
  debt                                                                          
  ext…                                                                          
  Non…                                                                          
  net     $     13,3…       $     (19,…  )    $     (16,…  )    $     (98,…  )  
  inc…                                                                          
  (lo…                                                                          
  Non…                                                                          
  net                                                                           
  inc…                                                                          
  (lo…                                                                          
  per     $      0.07       $     (0.11  )    $     (0.09  )    $     (0.57  )  
  sha…                                                                          
  bas…                                                                          
  and                                                                           
  dil…                                                                          
  Wei…                                                                          
  ave…                                                                          
  com…                                                                          
  sha…          181,…             174,…             180,…             172,…     
  out…                                                                          
  bas…                                                                          
  and                                                                           
  dil…                                                                          
                                                                                
(1) Fair value changes include gains and losses related to quarterly fair value
adjustments of our marketable equity securities and indemnity-related holdback
liabilities. (2) Acquisition related expenses consist of legal, diligence,
accounting, and financing costs incurred for acquisitions during the three and
nine months ended September 30, 2026 and 2025. Adjusted EBITDA
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net     $     (14,…  )    $     (79,…  )    $     (135…  )    $     (190…  )  
  loss                                                                          
  Int…          (3,9…  )          (4,6…  )          (11,…  )          (7,5…  )  
  inc…                                                                          
  Int…          6,701             15,3…             31,3…             54,9…     
  exp…                                                                          
  Dep…          7,338             8,120             21,8…             24,3…     
  Amo…          18,8…             18,9…             56,5…             51,0…     
  Pro…                                                                          
  for                                                                           
  (be…             35               276               282             (45,…  )  
  fro…                                                                          
  inc…                                                                          
  tax…                                                                          
  EBI…    $     14,1…       $     (41,…  )    $     (36,…  )    $     (113…  )  
  Los…                                                                          
  (ga…                                                                          
  from          2,368             (1,5…  )          8,318             2,465     
  equ…                                                                          
  met…                                                                          
  inv…                                                                          
  Fair                                                                          
  val…          (41,…  )          1,255             (107…  )          (4,4…  )  
  cha…                                                                          
  Sto…                                                                          
  com…          48,0…             33,9…             154,…             79,4…     
  exp…                                                                          
  Emp…                                                                          
  pay…                                                                          
  tax                                                                           
  rel…          2,749             1,039             7,800             8,165     
  to                                                                            
  sto…                                                                          
  com…                                                                          
  Acq…                                                                          
  rel…          3,728               552             4,714             6,073     
  exp…                                                                          
  Amo…                                                                          
  of            (3,9…  )          (3,9…  )          (11,…  )          (11,…  )  
  tec…                                                                          
  lic…                                                                          
  Fra…                                                                          
  tax…                                                                          
  rel…              —                 —                 —             1,647     
  to                                                                            
  IPO                                                                           
  Loss                                                                          
  on                —             12,0…             11,6…             12,0…     
  debt                                                                          
  ext…                                                                          
  Adj…    $     25,5…       $     1,476       $     30,7…       $     (20,…  )  
  EBI…                                                                          
                                                                                
(1) Fair value changes include gains and losses related to quarterly fair value
adjustments of our marketable equity securities and indemnity-related holdback
liabilities. (2) Acquisition related expenses consist of legal, diligence,
accounting, and financing costs incurred for acquisitions during the three and
nine months ended September 30, 2026 and 2025.

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TEM/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.